Genovis' Q4 2025 report showed strong growth following the SEK10.9m ADC order as expected. Despite some fx-headwinds, the outlook for 2026 appears strong with improving demand among biotech customers and a net cash position of around 15% of market cap ready to be utilized. The stock trades at 22x-9x 2026e-2028e EV/EBITDA.
LÄS MER